Therapeutic Dosing of Synthetic Antimi Further Demonstrates the Potential of microRNA-208 Inhibition in Treatment of Chronic Heart Failure
Research by miRagen Therapeutics publishedin CirculationBOULDER, Colo.–(BUSINESS WIRE)–Sep 6, 2011 – miRagenTherapeutics, Inc., a preclinical-stage biopharmaceutical companyfocused on improving patients’ lives by developing innovativemicroRNA…
September 6th, 2011
Posted in
Drug